Non-Hodgkin’s disease

Adult Hodgkin s disease Non-Hodgkin s disease Trophoblastic choriocarcinoma Testicular and ovarian germ cell cancers... 

Vascular tmnors Angiosarcoma Hemangiosarcoma Epithelioid hemangioendothelioma Leiomyosarcoma Fibrosarcoma Embryonal sarcoma Fibrous histiocytoma Lymphoma (Hodgkin s disease) Lymphoma (non-Hodgkin s disease)... 

In Hodgkin s disease, a Reed-Sternberg variant type of cell is accepted as evidence for liver involvement. Typically these cells are rarely identified in biopsy specimens (Jaffe 1987). In non-Hodgkin s disease, the lymphocytic form tends to be miliary, whereas the large cells or histiocytic varieties are nodular masses (Ryan et al. 1988). In both Hodgkin s and non-Hodgkin s lymphoma initial involvement is seen in the portal areas, because this is where the majority of the lymphatic tissue of the liver is found. 

USP (Oncovin) vindesine sulfate [59917-39 ] C43H55N5O7 -H2S0 852.01 (50) chil-dren lymphocytic leukemia Hodgkin s disease non-Hodg-kin s lymphomas Wilm s tumor neuroblastoma rhabdomyosarcoma, investigational dmg (paresthesias, foot drop, double vision, etc) constipation ileus alopecia leu-kopenia (occasional) ... 

Delineate the clinical course of follicular indolent and diffuse aggressive non-Hodgkin s lymphoma and the implications for disease classification schemes and treatment goals. 

Cancers Multiple myeloma Non-Hodgkin s lymphoma Hodgkin s disease Acute myeloid leukemia Neuroblastoma Germ cell tumors Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative disorders Non-Hodgkin s lymphoma Hodgkin s disease Chronic lymphocytic leukemia Multiple myeloma... 

Low- and intermediate-grade non-Hodgkin s lymphoma Hodgkin s disease... 

Cancer. A small non-significant excess of respiratory cancers among phenol-exposed wood industry workers was not clearly related to phenol exposure (Kauppinen et al. 1986). Although small nonsignificant excesses of Hodgkin s disease and of lung, esophageal, and kidney cancers were noted, mortality from cancer was not clearly related to phenol exposure in phenol production workers (Dosemeci et al. 1991). 

Because of its antiviral and anticancer effects, IFN-a is used in the treatment of hepatitis and various forms of cancer, such as Kaposi s sarcoma, non-Hodgkin s lymphoma, and hairy cell leukemia. Exhibit 4.8 describes the treatment of hepatitis C with IFN- . IFN-jS is used for treating multiple sclerosis, a chronic disease of the nervous system. The medical application of IFN-y is for cancer, AIDS, and leprosy. 

Recent review papers have covered in detail the available cUnical results with the mXOR inhibitors [151,156]. Overall, the compounds are well tolerated and may induce prolonged stable disease and increase time to progression in a subset of cancer patients. In particular, promising activity has been reported for CCl-779 in patients with mantle cell non-Hodgkin s lymphoma [151]. 

Vinblastine is used for severe lymphoblastic leukemia, Hodgkin s disease, non-Hodgkin s lymphoma, neuroblastoma, sarcoma, and other cancerous diseases. Synonyms of this drug are velban, eczal, and others. 

---